Extraordinary clinical response to ibrutinib in low-grade ovarian cancer guided by organoid drug testing

Heidi J. Gray(Seattle Cancer Care Alliance), Carla Grandori(Precision for Medicine (United States)), Lauren Appleyard(Precision for Medicine (United States)), Hallie A. Swan(Precision for Medicine (United States)), Kalyan Banda(University of Washington), Barbara A. Goff(University of Washington), D. Peretti(Precision for Medicine (United States)), Maddy Pollastro(Precision for Medicine (United States)), Payel Chatterjee(Precision for Medicine (United States)), Rachele Rosati(Precision for Medicine (United States)), Brady Bernard(Providence Portland Medical Center), Elizabeth M. Swisher(University of Washington), Grace Durenberger(Precision for Medicine (United States)), Astrid Margossian(Precision for Medicine (United States)), Christopher J. Kemp(Fred Hutch Cancer Center), Robert L. Diaz, Katannya Kapeli(University of California, San Diego), Shalini Pereira(Precision for Medicine (United States)), Trevor Ainge(Precision for Medicine (United States))

npj Precision Oncology

May 18, 2023

Cited by 26

|Nature|2014|6.5k

|Cell|2013|5.2k

|Annual Review of Cell and Developmental Biology|2000|1.3k

|Cancer Discovery|2017|964

|Nature Genetics|1999|903

Related Papers